100% Disease Control Achieved in 5 Recurrent Glioblastoma Patients with Immunotherapy and Optune Device Combination

ImmunityBio reports 100% disease control in 5 out of 5 patients with recurrent glioblastoma treated with ANKTIVA and Optune Gio device. The combination of ANKTIVA, an IL-15 agonist, NK cell therapy, and Optune immune-stimulating device resulted in near complete response in 2 patients and stable disease in 2 others. The findings are encouraging given the low survival rates associated with GBM, and the company plans to conduct a Phase 2 trial to further evaluate the potential of this treatment.